# Clinical Trial Compliance Requirements

**Version**: 1.0
**Audience**: Product Requirements
**Last Updated**: 2025-01-24
**Status**: Draft

> **See**: dev-compliance-practices.md for implementation guidance
> **See**: prd-database.md for data architecture
> **See**: ops-security.md for operational procedures

---

## Executive Summary

Clinical trial systems must comply with strict regulations to ensure data integrity and patient safety. This system meets all requirements for electronic clinical trial data collection in the United States and European Union.

**Primary Regulations**:
- FDA 21 CFR Part 11 (United States)
- ALCOA+ Data Integrity Principles
- HIPAA (when applicable)
- GDPR (European participants)

---

## Why Compliance Matters

**For Regulators**:
- Ensures clinical trial data is trustworthy
- Protects patients participating in trials
- Maintains integrity of drug approval process

**For Sponsors**:
- Required for regulatory submission
- Reduces risk of study rejection
- Protects company reputation

**For Patients**:
- Guarantees their data is handled properly
- Ensures privacy protection
- Maintains trust in clinical research

---

## Key Requirements

# REQ-p00010: FDA 21 CFR Part 11 Compliance

**Level**: PRD | **Implements**: p00044 | **Status**: Draft

The system SHALL meet all FDA 21 CFR Part 11 requirements for electronic records and electronic signatures used in clinical trials.

Compliance SHALL include:
- Validation that system performs as intended
- Ability to generate accurate and complete copies of records
- Protection of records to enable accurate and ready retrieval
- Audit trails for record creation, modification, and deletion
- Operational checks to enforce permitted sequencing of steps
- Authority checks to ensure only authorized individuals can use the system
- Device checks to determine validity of source of data input
- Determination that persons using electronic signatures are who they claim to be

**Rationale**: FDA 21 CFR Part 11 is the regulatory foundation for electronic clinical trial systems in the United States. Compliance is mandatory for regulatory submission acceptance and protects the integrity of clinical trial data used for drug approval decisions.

**Acceptance Criteria**:
- System validation documentation package complete
- Formal requirements with traceability maintained (see REQ-p00036 in prd-requirements-management.md)
- All record changes captured in tamper-proof audit trail
- Electronic signatures meet FDA requirements
- System access controls prevent unauthorized use
- Records retrievable in human-readable form for FDA inspection

*End* *FDA 21 CFR Part 11 Compliance* | **Hash**: 62500780
---

# REQ-p00011: ALCOA+ Data Integrity Principles

**Level**: PRD | **Implements**: p00010 | **Status**: Draft

All clinical trial data SHALL adhere to ALCOA+ principles ensuring data quality and integrity throughout the data lifecycle.

ALCOA+ compliance SHALL ensure data is:
- **Attributable**: Clearly linked to the person who created it
- **Legible**: Readable and understandable (permanent, not obscured)
- **Contemporaneous**: Recorded at time of observation
- **Original**: First recording or certified true copy
- **Accurate**: Free from errors, complete and correct
- **Complete**: All data captured, nothing missing
- **Consistent**: Performed in same manner over time
- **Enduring**: Preserved for entire retention period
- **Available**: Accessible for review and audit when needed

**Rationale**: ALCOA+ principles are internationally recognized data integrity standards. Adhering to these principles ensures clinical trial data is trustworthy, defensible, and acceptable to regulators worldwide.

**Acceptance Criteria**:
- Every data entry includes creator identification and timestamp
- Original values preserved when data modified
- Data recorded at or near time of observation
- Data readable without special tools or decoding
- Complete audit trail available for entire data lifecycle

*End* *ALCOA+ Data Integrity Principles* | **Hash**: 05c9dc79
---

# REQ-p00012: Clinical Data Retention Requirements

**Level**: PRD | **Implements**: p00010 | **Status**: Draft

Clinical trial data and associated audit trails SHALL be retained for minimum period required by regulations (typically 7+ years after study completion or product approval).

Data retention SHALL ensure:
- All clinical trial records preserved for required period
- Audit trails retained with associated clinical data
- Data remains readable and accessible throughout retention period
- Export capability for regulatory submission and archival
- Retention period tracked and enforced per study

**Rationale**: Regulatory agencies require long-term retention of clinical trial data to support product approvals, post-market surveillance, and potential future investigations. Data must remain accessible and readable despite technology changes over retention period.

**Acceptance Criteria**:
- Retention period configurable per study/jurisdiction
- Data export includes complete audit trail
- Exported data readable without proprietary systems
- Retention period enforcement prevents premature deletion
- Data integrity maintained throughout retention period

*End* *Clinical Data Retention Requirements* | **Hash**: b3332065
---

# REQ-p01061: GDPR Compliance

**Level**: PRD | **Implements**: p00044 | **Status**: Draft

The system SHALL comply with the EU General Data Protection Regulation (GDPR) for processing personal data of EU clinical trial participants.

GDPR compliance SHALL include:
- Lawful basis for processing (explicit consent or legitimate interest for clinical trials)
- Data subject rights (access, rectification, erasure where applicable, portability)
- Data minimization (collect only data necessary for trial purposes)
- Privacy by design (protection built into system architecture)
- Data Processing Agreements with all processors
- Breach notification within 72 hours to supervisory authority

**Rationale**: Clinical trials conducted in the EU or involving EU residents must comply with GDPR. Non-compliance risks fines up to â‚¬20M or 4% of global turnover and invalidates trial data for regulatory submissions.

**Acceptance Criteria**:
- Privacy policy documents GDPR lawful basis for processing
- Data subject request workflow implemented and documented
- Data Processing Agreements in place with all third-party processors
- Breach notification procedure documented and tested
- Data Protection Impact Assessment completed for clinical trial processing

*End* *GDPR Compliance* | **Hash**: 0f9e0f11
---

# REQ-p01062: GDPR Data Portability

**Level**: PRD | **Implements**: p01061 | **Status**: Draft

Patients SHALL be able to export their personal clinical diary data in a portable, machine-readable format to exercise GDPR Article 20 data portability rights.

Data portability SHALL provide:
- Patient-initiated export of all their diary entries and health records
- Export in standard machine-readable format (JSON)
- Complete data including timestamps, values, and metadata
- Export available through mobile app without requiring sponsor assistance
- Import capability to restore data on same or different device

**Rationale**: GDPR Article 20 grants EU data subjects the right to receive their personal data in a structured, commonly used, machine-readable format. Clinical trial participants must be able to obtain their own health diary data for personal records or transfer to another system.

**Acceptance Criteria**:
- Patient can export all their diary data from mobile app
- Export file contains complete diary entries in JSON format
- Export includes all user-generated content and timestamps
- Patient can import previously exported data
- Export/import does not require network connectivity
- Exported data excludes system internals (sync state, device IDs)

*End* *GDPR Data Portability* | **Hash**: 02cd6237
---

### System Validation

**What It Means**: The system must be tested and proven to work correctly before use in clinical trials.

**Requirements**:
- Documented test plans and results
- Proof that system does what it claims
- Regular revalidation after changes
- Traceability from requirements to tests

**Benefits**: Provides confidence that the system produces reliable data and won't lose or corrupt patient entries.

---

### Secure Access Control

**What It Means**: Only authorized people can access the system, and each person can only see data they're permitted to view.

**Requirements**:
- Unique user accounts for each person
- Strong password requirements
- Multi-factor authentication for staff
- Automatic logout after inactivity
- Records of all access attempts

**Patient Protection**: Patients can only see their own data. Study staff can only access data at their assigned clinical sites.

---

### Electronic Signatures

**What It Means**: Every action in the system is electronically "signed" by the person performing it.

**Requirements**:
- Records who performed the action
- Records when the action occurred
- Records what the action meant (created, updated, etc.)
- Signature permanently linked to the record

**Implementation**: Automatic - users don't need to explicitly "sign" each action. The system captures their identity with every entry.

---

## Regulatory Submission

When sponsors submit clinical trial data to regulators:

**What Regulators Review**:
- Complete audit trail showing all data changes
- System validation documentation
- Evidence of proper access controls
- Proof that data integrity was maintained

**What This System Provides**:
- Exportable audit logs in standard formats
- Validation documentation package
- Access control reports
- Data integrity verification tools

---

## Data Retention

**Requirements**:
- Clinical trial data must be retained for minimum period (typically 7+ years)
- Audit trails must be retained with the data
- System must ensure data remains accessible and readable

**Compliance**: The system uses standard formats and includes tools for long-term data export and archival.

---

## Privacy Regulations

### HIPAA (United States)

When applicable, the system protects health information:
- Encryption of data at rest and in transit
- Access controls limit who can see data
- Audit logs track all access to patient records
- Patient rights to access their own data

### GDPR (European Union)

For EU participants:
- Data minimization (collect only what's needed)
- Right to access personal data
- Right to data portability
- Right to be forgotten (with clinical trial exceptions)
- Consent management

---

## Compliance Benefits

**Risk Reduction**:
- Lower chance of study rejection by regulators
- Protection against data integrity challenges
- Defense against compliance violations

**Efficiency**:
- Automated compliance reduces manual oversight
- Built-in audit trails eliminate separate documentation
- Faster regulatory review process

**Trust**:
- Patients confident their data is protected
- Sponsors confident in data quality
- Regulators confident in data integrity

---

## References

- **Implementation Details**: dev-compliance-practices.md
- **Data Architecture**: prd-database.md
- **Security Architecture**: prd-security.md
- **Operations**: ops-security.md
- **FDA Guidance**: FDA 21 CFR Part 11
- **ALCOA+ Principles**: Data Integrity and Compliance Guidelines
